A Philadelphia cancer lab is betting that a bit of clever DNA engineering can help T cells hit ovarian tumors harder and longer, all from a single shot.
Researchers at The Wistar Institute say they have built a DNA-delivered bispecific T cell engager, or BTE, that tightened control of ovarian tumors in preclinical tests. The system leans on a so-called knob-into-hole DNA platform that forces the assembly of multivalent BTEs and lets one dose generate two different antigen-targeting molecules at once. In mouse models, the experimental treatment slowed tumor growth and also showed activity against cells taken directly from ovarian cancer patients.
As reported by PHILADELPHIA.Today, the study was led by postdoctoral fellow Pratik S. Bhojnagarwala in the lab of vaccine and immunotherapy veteran David B. Weiner, with collaborators from the University of Pennsylvania. A Wistar news release distributed on EurekAlert! notes that the DNA platform could cut manufacturing costs and reduce dosing needs because muscle cells keep churning out the therapeutic protein over time.
How the DNA knob-into-hole system builds the drug in muscle
The peer-reviewed paper in Molecular Therapy breaks down the mechanics. Complementary "knob" and "hole" Fc chains are encoded on separate plasmids so that they pair only when co-expressed in the same cell, which helps enforce controlled heterodimer formation and cuts down on unwanted homodimers.
The DNA is delivered into muscle and assisted by electroporation, a brief electrical pulse that helps cells take up the plasmids. Once inside, the muscle tissue becomes a sort of protein factory, driving sustained in-body production and secretion of the bispecific antibodies instead of relying on repeated infusions of recombinant protein.
What the early data show in mice and lab tests
According to EurekAlert!, Wistar reports that the DNA-assembled BTEs stuck around longer in circulation and were more effective at slowing tumor growth in mice than traditional BTE formats. In lab dishes, the same approach killed patient-derived ovarian tumor cells.
The team also saw a boost when they combined the DNA-BTE with an immune checkpoint inhibitor. That pairing further amplified tumor control in the preclinical models, hinting that this platform might eventually slot into combination immunotherapy strategies rather than standing alone.
Big upside, big questions
A review of DNA-based immunotherapy in Molecular Therapy notes that in-body expression platforms can stretch out drug exposure and ease dosing burdens, an appealing prospect for complex and costly bispecifics like these. That kind of durability could be a feature or a bug, depending on how safe and controllable the expression turns out to be in humans.
For now, the usual caveats apply. Moving from mice to people means fresh questions about safety, dose levels and potential immune reactions to the DNA and the long-lived antibodies it encodes. Those are the kinds of issues only carefully staged clinical trials can settle.
Philly roots and what comes next
The paper lists co-authors from The Wistar Institute and the Perelman School of Medicine at the University of Pennsylvania, underscoring how much of this work is homegrown in West Philadelphia. News coverage says the group plans to put the therapy through more advanced human cell models as the next step toward eventual human trials, according to News-Medical.
Funders named in the release include the W.W. Smith Charitable Trust along with private foundations that support translational cancer research, the kind designed to nudge lab discoveries toward the clinic.
For patients, though, nothing changes yet. The findings remain an encouraging preclinical advance rather than a ready-made treatment. "I think it's a major advancement for the field of bispecific antibodies," Bhojnagarwala said, as reported by PHILADELPHIA.Today, while stressing that more work is needed before the approach is tested in people.
